Looking to sell ArsenalBio stock or options?Contact us
ArsenalBio operates as a programmable cell therapy company with a purpose to discover, develop, and market curative immune cell therapies. The company features a comprehensive research and development engine that creates multifunctional T-cell medicines, made possible by the accurate and specific insertion of large synthetic deoxyribonucleic acid sequences. Therefore, ArsenalBio provides clinicians with advanced autologous T-cell therapies to conquer cancer.
Kenneth Drazan, Green Sands Equity, UCSF Foundation Investment Company, Byers Capital, Triatomic Capital, University of California, Parker Institute for Cancer Immunotherapy, Waycross Ventures, Bristol-Myers Squibb, Osage University Partners, Emerson Collective, Westlake Village BioPartners, Hitachi Ventures, Sixth Street Partners, SoftBank Investment Advisers, Euclidean Capital.
We have an even better solution: The Collective Exchange Fund
Get in touch and see if we can help you